Diabetic status aggravates atherosclerosis in aged ApoE^–/– mice

References

[1] Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2019;394(10204):1145-1158.

[2] Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56.

[3] Jaeger BC, Anstey DE, Bress AP, et al. Cardiovascular disease and mortality in adults aged ≥60 years according to recommendations by the American College of Cardiology/American Heart Association and American College of Physicians/American Academy of family physicians. Hypertension. 2019;73(2):327-334.

[4] Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with Ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425-1435.

[5] Wang T, Dong Y, Yao L, et al. Adoptive transfer of metabolically reprogrammed macrophages for atherosclerosis treatment in diabetic ApoE–/– mice. Bioact Mater. 2022;16:1682-1694.

RIGHTS & PERMISSIONS

2023 The Authors. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.